TY - JOUR
T1 - Radiologic–Pathologic Correlation of Solid Portions on Thin-section CT Images in Lung Adenocarcinoma
T2 - A Multicenter Study
AU - Investigators of JSTR Lung Cancer Working Group
AU - Yanagawa, Masahiro
AU - Kusumoto, Masahiko
AU - Johkoh, Takeshi
AU - Noguchi, Masayuki
AU - Minami, Yuko
AU - Sakai, Fumikazu
AU - Asamura, Hisao
AU - Tomiyama, Noriyuki
AU - Awai, Kazuo
AU - Minami, Manabu
AU - Endo, Masahiro
AU - Aoki, Takatoshi
AU - Ashizawa, Kazuto
AU - Sakai, Shuji
AU - Hara, Masaki
AU - Watanabe, Hirokazu
AU - Takenaka, Daisuke
AU - Komoto, Daisuke
AU - Uchikawa, Yoko
AU - Koizumi, Naoya
AU - Adachi, Shuji
AU - Fujimoto, Kiminori
AU - Hatabu, Hiroto
AU - Kurihara, Yasuyuki
AU - Murata, Kiyoshi
AU - Murayama, Sadayuki
AU - Nakajima, Yasuo
AU - Ohno, Yoshiharu
AU - Takahashi, Koji
AU - Takahashi, Masashi
AU - Tanaka, Nobuyuki
N1 - Funding Information:
The present study was supported in part by the National Cancer Center Research and Development Fund (grant 23-A-25) and by the Japanese Society of Thoracic Radiology members and Japan Lung Cancer Society of Pathology Diagnosis committee members. The authors thank the following pathologists for their pathological central review: Drs. Masayuki Noguchi (Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba), Yuko Minami (Department of Pathology, National Hospital Organization Ibarakihigashi National Hospital, the Center of Chest Diseases and Severe Motor and Intellectual Disabilities), Yuichi Ishikawa (Division of Pathology, the Cancer Institute Hospital of JFCR), Yosihiro Matsuno (Department of Surgical Pathology, Hokkaido University Hospital), Koji Tsuta (Pathology and Laboratory Medicine, Kansai Medical University), Noriko Motoi (Department of Pathology, National Cancer Center Hospital), and Shingo Sakashita (Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba). The authors also thank Mr. Kouhei Inoue (statistician, EPS Corporation, Tokyo, Japan) for his suggestions and assistance concerning the statistical analysis of the data. The JSTR Lung Cancer Working Group: Hiroshima University, Hiroshima, Japan (Kazuo Awai, MD, PhD); University of Tsukuba Hospital, Ibaraki, Japan (Manabu Minami, MD, PhD); Shizuoka Cancer Center, Shizuoka, Japan (Masahiro Endo, MD, PhD); University of Occupational and Environmental Health School of Medicine, Kitakyushu, Japan (Takatoshi Aoki, MD, PhD); Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan (Kazuto Ashizawa, MD, PhD); Tokyo Women's Medical University, Tokyo, Japan (Shuji Sakai, MD, PhD); Nagoya City West Medical Center, Nagoya, Japan (Masaki Hara, MD, PhD); National Cancer Center, Tokyo, Japan (Hirokazu Watanabe, MD, PhD); Hyogo Cancer Center, Hyogo, Japan (Daisuke Takenaka, MD); Hiroshima City Asa Citizens Hospital, Hiroshima, Japan (Daisuke Komoto, MD, PhD); Hitachi General Hospital, Ibaraki, Japan (Yoko Uchikawa, MD); Niigata Cancer Center Hospital, Niigata, Japan (Naoya Koizumi, MD); Kita-Harima Medical Center, Hyogo, Japan (Shuji Adachi, MD, PhD); Kurume University School of Medicine, Fukuoka, Japan (Kiminori Fujimoto, MD, PhD); Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA (Hiroto Hatabu, MD, PhD); St. Luke's International Hospital, Tokyo, Japan (Yasuyuki Kurihara, MD); Shiga University of Medical Science, Shiga, Japan (Kiyoshi Murata, MD, PhD); University of the Ryukyus, Okinawa, Japan (Sadayuki Murayama, MD, PhD); St. Marianna University School of Medicine, Kanagawa, Japan (Yasuo Nakajima, MD, PhD); Kobe University Graduate School of Medicine, Hyogo, Japan (Yoshiharu Ohno, MD, PhD); Asahikawa Medical University, Hokkaido, Japan (Koji Takahashi, MD, PhD); Yujin-Yamazaki Hospital, Shiga, Japan (Masashi Takahashi, MD); Saiseikai Yamaguchi General Hospital, Yamaguchi, Japan (Nobuyuki Tanaka, MD).
Funding Information:
The present study was supported in part by the National Cancer Center Research and Development Fund (grant 23-A-25 ) and by the Japanese Society of Thoracic Radiology members and Japan Lung Cancer Society of Pathology Diagnosis committee members. The authors thank the following pathologists for their pathological central review: Drs. Masayuki Noguchi (Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba), Yuko Minami (Department of Pathology, National Hospital Organization Ibarakihigashi National Hospital, the Center of Chest Diseases and Severe Motor and Intellectual Disabilities), Yuichi Ishikawa (Division of Pathology, the Cancer Institute Hospital of JFCR), Yosihiro Matsuno (Department of Surgical Pathology, Hokkaido University Hospital), Koji Tsuta (Pathology and Laboratory Medicine, Kansai Medical University), Noriko Motoi (Department of Pathology, National Cancer Center Hospital), and Shingo Sakashita (Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba). The authors also thank Mr. Kouhei Inoue (statistician, EPS Corporation, Tokyo, Japan) for his suggestions and assistance concerning the statistical analysis of the data. The JSTR Lung Cancer Working Group: Hiroshima University, Hiroshima, Japan (Kazuo Awai, MD, PhD); University of Tsukuba Hospital, Ibaraki, Japan (Manabu Minami, MD, PhD); Shizuoka Cancer Center, Shizuoka, Japan (Masahiro Endo, MD, PhD); University of Occupational and Environmental Health School of Medicine, Kitakyushu, Japan (Takatoshi Aoki, MD, PhD); Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan (Kazuto Ashizawa, MD, PhD); Tokyo Women's Medical University, Tokyo, Japan (Shuji Sakai, MD, PhD); Nagoya City West Medical Center, Nagoya, Japan (Masaki Hara, MD, PhD); National Cancer Center, Tokyo, Japan (Hirokazu Watanabe, MD, PhD); Hyogo Cancer Center, Hyogo, Japan (Daisuke Takenaka, MD); Hiroshima City Asa Citizens Hospital, Hiroshima, Japan (Daisuke Komoto, MD, PhD); Hitachi General Hospital, Ibaraki, Japan (Yoko Uchikawa, MD); Niigata Cancer Center Hospital, Niigata, Japan (Naoya Koizumi, MD); Kita-Harima Medical Center, Hyogo, Japan (Shuji Adachi, MD, PhD); Kurume University School of Medicine, Fukuoka, Japan (Kiminori Fujimoto, MD, PhD); Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA (Hiroto Hatabu, MD, PhD); St. Luke's International Hospital, Tokyo, Japan (Yasuyuki Kurihara, MD); Shiga University of Medical Science, Shiga, Japan (Kiyoshi Murata, MD, PhD); University of the Ryukyus, Okinawa, Japan (Sadayuki Murayama, MD, PhD); St. Marianna University School of Medicine, Kanagawa, Japan (Yasuo Nakajima, MD, PhD); Kobe University Graduate School of Medicine, Hyogo, Japan (Yoshiharu Ohno, MD, PhD); Asahikawa Medical University, Hokkaido, Japan (Koji Takahashi, MD, PhD); Yujin-Yamazaki Hospital, Shiga, Japan (Masashi Takahashi, MD); Saiseikai Yamaguchi General Hospital, Yamaguchi, Japan (Nobuyuki Tanaka, MD).
Publisher Copyright:
© 2017 The Author(s)
PY - 2018/5
Y1 - 2018/5
N2 - Although the invasiveness size on computed tomography (CT) is important for the T descriptor, the solid portion size on CT will be larger than the pathologic invasiveness size. We analyzed whether the maximal dimensions of the solid portions on CT correlated with the pathologic invasiveness size (> 0.5 cm) in 378 lung adenocarcinoma patients. A solid portion > 0.8 cm on the lung window setting or > 0.6 cm on the mediastinal window setting predicted for pathologic invasiveness > 0.5 cm. Background: Measuring the size of invasiveness on computed tomography (CT) for the T descriptor size was deemed important in the 8th edition of the TNM lung cancer classification. We aimed to correlate the maximal dimensions of the solid portions using both lung and mediastinal window settings on CT imaging with the pathologic invasiveness (> 0.5 cm) in lung adenocarcinoma patients. Materials and Methods: The study population consisted of 378 patients with a histologic diagnosis of adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (IVA)-lepidic, IVA-acinar and/or IVA-papillary, and IVA-micropapillary and/or solid adenocarcinoma. A panel of 15 radiologists was divided into 2 groups (group A, 9 radiologists; and group B, 6 radiologists). The 2 groups independently measured the maximal and perpendicular dimensions of the solid components and entire tumors on the lung and mediastinal window settings. The solid proportion of nodule was calculated by dividing the solid portion size (lung and mediastinal window settings) by the nodule size (lung window setting). The maximal dimensions of the invasive focus were measured on the corresponding pathologic specimens by 2 pathologists. Results: The solid proportion was larger in the following descending order: IVA-micropapillary and/or solid, IVA-acinar and/or papillary, IVA-lepidic, MIA, and AIS. For both groups A and B, a solid portion > 0.8 cm in the lung window setting or > 0.6 cm in the mediastinal window setting on CT was a significant indicator of pathologic invasiveness > 0.5 cm (P <.001; receiver operating characteristic analysis using Youden's index). Conclusion: A solid portion > 0.8 cm on the lung window setting or solid portion > 0.6 cm on the mediastinal window setting on CT predicts for histopathologic invasiveness to differentiate IVA from MIA and AIS.
AB - Although the invasiveness size on computed tomography (CT) is important for the T descriptor, the solid portion size on CT will be larger than the pathologic invasiveness size. We analyzed whether the maximal dimensions of the solid portions on CT correlated with the pathologic invasiveness size (> 0.5 cm) in 378 lung adenocarcinoma patients. A solid portion > 0.8 cm on the lung window setting or > 0.6 cm on the mediastinal window setting predicted for pathologic invasiveness > 0.5 cm. Background: Measuring the size of invasiveness on computed tomography (CT) for the T descriptor size was deemed important in the 8th edition of the TNM lung cancer classification. We aimed to correlate the maximal dimensions of the solid portions using both lung and mediastinal window settings on CT imaging with the pathologic invasiveness (> 0.5 cm) in lung adenocarcinoma patients. Materials and Methods: The study population consisted of 378 patients with a histologic diagnosis of adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (IVA)-lepidic, IVA-acinar and/or IVA-papillary, and IVA-micropapillary and/or solid adenocarcinoma. A panel of 15 radiologists was divided into 2 groups (group A, 9 radiologists; and group B, 6 radiologists). The 2 groups independently measured the maximal and perpendicular dimensions of the solid components and entire tumors on the lung and mediastinal window settings. The solid proportion of nodule was calculated by dividing the solid portion size (lung and mediastinal window settings) by the nodule size (lung window setting). The maximal dimensions of the invasive focus were measured on the corresponding pathologic specimens by 2 pathologists. Results: The solid proportion was larger in the following descending order: IVA-micropapillary and/or solid, IVA-acinar and/or papillary, IVA-lepidic, MIA, and AIS. For both groups A and B, a solid portion > 0.8 cm in the lung window setting or > 0.6 cm in the mediastinal window setting on CT was a significant indicator of pathologic invasiveness > 0.5 cm (P <.001; receiver operating characteristic analysis using Youden's index). Conclusion: A solid portion > 0.8 cm on the lung window setting or solid portion > 0.6 cm on the mediastinal window setting on CT predicts for histopathologic invasiveness to differentiate IVA from MIA and AIS.
KW - Invasiveness size
KW - Pathologic invasiveness
KW - Radiological Prediction
KW - Solid portion size
KW - TNM lung cancer classification (8th edition)
UR - http://www.scopus.com/inward/record.url?scp=85039923384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039923384&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2017.12.005
DO - 10.1016/j.cllc.2017.12.005
M3 - Article
C2 - 29307591
AN - SCOPUS:85039923384
SN - 1525-7304
VL - 19
SP - e303-e312
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 3
ER -
